Follow-up: Prozac intrigue fizzles

Article

In February ( http://www.contemporarypediatrics.com/contpeds/article/articleDetail.jsp?id=147795), Updates reported an accusation made by the British Medical Journal (BMJ) that pharmaceutical manufacturer Eli Lilly & Co. had concealed documents linking the company's antidepressant Prozac (fluoxetine) to a heightened risk of suicide. Updates noted that Lilly denied the allegation but, regrettably, the February issue of Contemporary Pediatrics had already gone to press when BMJ editors retracted their statement and apologized to Lilly: "The BMJ accepts that Eli Lilly acted properly in relation to the disclosure of these documents ... and is happy to set the record straight and apologize."

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
David Brousseau, MD, highlights impact of timely opioid dosing in pediatric sickle cell pain
August's FDA Focus: Approvals and pipeline updates in pediatrics | Image credit: Contemporary Pediatrics
© 2025 MJH Life Sciences

All rights reserved.